Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q4 2015 · 10-K
Revenue$1.31M$1.31M−21.6% vs Q4 2014 Net Income-$13.51M-$13.51MN/M vs Q4 2014 EPS Diluted-$0.16-$0.16N/M vs Q4 2014 Gross Profitderived$1,305,713−21.1% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Income-$21,707,000N/M Operating Cash Flowderived-$13,947,000N/M Free Cash Flowderived-$14,674,000N/M Margins · derivedGross margin100.0%+0.5 pt vs Q4 2014
Operating margin-1662.1%−796.9 pt vs Q4 2014
Net margin-1034.2%−399.5 pt vs Q4 2014
ended Dec 31, 2015 · filed Mar 15, 2016 · 75 d after period end